On Wednesday, Bio-Rad Labs A got an upgrade to its Relative Strength (RS) Rating, from 69 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks compares to the rest of the market.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating of at least 80 as they launch their biggest price moves. See if Bio-Rad Labs A can continue to show renewed price strength and clear that threshold.
Bio-Rad Labs A is not currently showing a potential buy point. See if the stock goes on to form a promising consolidation that could kick off a new price move.
While EPS growth fell last quarter from 10% to -16%, the top line grew 2%, up from -4% in the prior report.
Bio-Rad Labs A earns the No. 16 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, Tempus AI and Fortrea Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
